Biotech News
Amarin Highlights New Data on Lipoprotein(a) and other Apolipoprotein B Containing Lipoproteins at American Heart Association (AHA) Scientific Sessions 2026
Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted new clinical data evaluating lipoprotein(a) [Lp(a)] and other apolipoprotein B (apoB) containing lipoproteins as predictors of major adverse cardiovascular events (MACE), as well as new mechanistic findings examining the effects of eicosapentaenoic acid (EPA) on Lp(a) oxidation and related inflammatory and oxidative stress pathways. The data were presented at the American Heart Association (AHA) Scientific Sessions 2026 this weekend in Chicago, Illinois.
